Any rhyme or reason as to why you value Zantrene at ~$200m?
The typical response I hear is "one drug, one opportunity and Phase 1". They don't consider the multiple clinically validated drug synergies over the years (not to mention single agent validation) nor the surprising lack of cardiotoxicity demonstrated at Sheba 2.0 (and historically) to be of any real value at all, bizarrely IMO.
General Comments / Chat, page-11096
-
-
- There are more pages in this discussion • 343 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.63 |
Change
-0.030(1.81%) |
Mkt cap ! $278.6M |
Open | High | Low | Value | Volume |
$1.67 | $1.67 | $1.62 | $145.5K | 88.95K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 9815 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.63 | 343 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 9815 | 1.625 |
2 | 2470 | 1.620 |
1 | 8347 | 1.610 |
4 | 12373 | 1.605 |
7 | 29439 | 1.600 |
Price($) | Vol. | No. |
---|---|---|
1.630 | 343 | 1 |
1.635 | 1100 | 1 |
1.650 | 53 | 1 |
1.655 | 1163 | 1 |
1.660 | 4075 | 1 |
Last trade - 14.51pm 10/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |